[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsIntervention group: hospitalized patients with moderate-sever covid-19 with stable vital signs who receive NAC. In this study, for each specific routine therapeutic regimen (regimen 1: kaletra+ hydroxychloroquine and regimen 2: atazanavir / ritonavir + hydroxychloroquine), two arms of 15 people are defined (15 people in the control group who will receive only the routine regimen and 15 people in the intervention group who will receive 600 mg oral NAC three times a day in addition to the routine regimen).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsControl group: hospitalized patients with moderate-sever covid-19 with stable vital signs who do not receive the NAC (N-acetyl cysteine) In this study, for each specific routine therapeutic regimen (regimen 1: kaletra+ hydroxychloroquine and regimen 2: atazanavir / ritonavir + hydroxychloroquine), two arms of 15 people are defined (15 people in the control group who will receive only the routine regimen and 15 people in the intervention group who will receive 600 mg oral NAC three times a day in addition to the routine regimen).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 850, "treatment_name": "N-acetylcysteine", "treatment_type": "Respiratory agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]